The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both https://mariamcjag326050.bligblogging.com/39761088/glp-3-retatrutide-a-comparative-analysis